Curated News
By: NewsRamp Editorial Staff
May 18, 2026
Viromed Medical and NEBU-TEC Partner to Revolutionize Equine Respiratory Care with Cold Plasma
TLDR
- Viromed secures exclusive global distribution rights for PulmoPlas in veterinary use, targeting high-demand equine respiratory market.
- Viromed's cold plasma technology combined with NEBU-TEC's nebulization devices creates a new inhalation therapy for respiratory diseases.
- The partnership aims to improve respiratory health in horses and potentially humans, offering effective treatments for widespread conditions.
- PulmoPlas vet, combining cold plasma with nebulization, launches in 2026 without needing approval for veterinary use.
Impact - Why it Matters
This partnership matters because it introduces a novel, non-invasive treatment for respiratory diseases in horses using cold plasma technology, addressing a common and costly issue in the equine industry. The combination with NEBU-TEC's nebulization expertise could also pave the way for human applications, potentially transforming how respiratory conditions are treated in both veterinary and human medicine. For horse owners and veterinarians, this means a new, effective therapeutic option that may reduce reliance on antibiotics and improve animal welfare. In the long term, the technology's success could accelerate innovation in respiratory care across species.
Summary
Viromed Medical AG, a pioneer in cold plasma technology, has signed a global distribution partnership with NEBU-TEC International med. Produkte Eike Kern GmbH, combining its PulmoPlas® platform with NEBU-TEC's advanced nebulization technology. The exclusive worldwide rights for veterinary applications aim to address respiratory diseases in horses, tapping into a significant market in European equine sports. NEBU-TEC, with 30 years of experience in aerosol medicine, provides inhalation devices that are Class IIa medical devices under EU MDR, paving the way for future human applications. The partnership leverages Viromed's cold plasma expertise and NEBU-TEC's inhalation solutions to create innovative therapeutic concepts for both animals and humans. Uwe Perbandt, CEO of Viromed, highlights the attractive market potential, while Eike Kern, Managing Director of NEBU-TEC, emphasizes the forward-looking nature of combining inhalative application with cold plasma. The market launch of PulmoPlas® vet is scheduled for later in 2026, with no approval required in veterinary medicine. This collaboration strengthens Viromed's international commercialization strategy and expands its strategic partnerships in cold plasma technology. For more details, visit the original release on NEWMEDIAWIRE.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Viromed Medical and NEBU-TEC Partner to Revolutionize Equine Respiratory Care with Cold Plasma
